Semaglutide 10MG

Product Overview

Semaglutide 10MG is a synthetic GLP-1 receptor-agonist research material, supplied as white to off-white lyophilised powder in a 10mg catalogue presentation (SKU SM10). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

Semaglutide research examines GLP-1-receptor activation, glucose-dependent signalling, endocrine responses and energy-regulation pathways. Published clinical results relate to regulated pharmaceutical products rather than this independently supplied lyophilised vial.

Identity and Specifications

• Product: Semaglutide 10MG
• SKU: SM10
• Format: White to off-white lyophilised powder
• Synonyms: Semaglutide, NN9535, NNC 0113-0217
• Catalogue purity specification: ≥99%
• CAS number: 910463-68-2
• Molecular formula: C187H291N45O59
• Molecular weight: 4114 g/mol
• Amount: 10mg

Catalogue Distinction

This is the 10mg listing for this identity. The related Semaglutide 20mg listing has a different labelled amount or volume and a separate SKU. The amount difference is not a dose recommendation. Unless a batch certificate states otherwise, the scientific identity and research limitations are shared while the quantity supplied differs.

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• GLP-1-receptor binding and signalling
• glucose-dependent insulin and glucagon pathways
• gastric and central energy-regulation mechanisms
• comparative incretin-receptor study design

Evidence Quality and Limitations

Evidence includes mechanistic studies and large randomised trials. These studies do not demonstrate batch equivalence, sterility, clinical suitability or authorised use of the ExtolX product.

Regulatory Context

UK-authorised semaglutide medicines are finished, regulated formulations with defined excipients, delivery systems and approved labelling. This lyophilised research material is not equivalent to those medicines and is not supplied for administration.

Storage and Handling

Before reconstitution: Keep the lyophilised vial sealed, dry and protected from light at −20°C or below, subject to the batch-specific supplier documentation. Published semaglutide reference-material data support frozen storage, but the exact form and formulation of this ExtolX batch have not been confirmed. Do not transfer storage conditions from a finished medicinal product.

After reconstitution: Stability depends on the exact salt or formulation, solvent, concentration, pH and container. Prepare only what the validated method requires. If that method supports frozen storage, use single-use aliquots and avoid repeated freeze–thaw cycles. Use clean laboratory technique, avoid vigorous agitation, and record the preparation and storage history. No numerical solution shelf life has been verified for this ExtolX batch.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• MedChemExpress storage references: Semaglutide and semaglutide acetate
• STEP 1 randomised trial (PMID 33567185)
• STEP 2 randomised trial (PMID 33667417)
• Semaglutide 20MG
• UK SmPC: semaglutide (Ozempic)

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.